Shionogi & Co., Ltd.
Stock Price Chart
2026/08/07 UpdatedPrice Trend
2026/08/07 UpdatedPrice & Trading Details
2026/08/07 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/07/01Earnings Calendar
Updated 2026/07/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/01/29 | ¥68.45 | ¥87.76 | +28.2% |
| 2025/10/27 | ¥50.55 | ¥51.93 | +2.7% |
| 2025/07/28 | ¥42.54 | ¥46.26 | +8.7% |
| 2025/05/12 | ¥43.20 | ¥43.06 | -0.3% |
Shareholder Composition
Updated 2026/07/01Top Mutual Funds / ETFs
Updated 2026/07/01Major Holders
Updated 2026/07/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
20.4M | +9.65% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
11.0M | +0.84% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.3M | +2.14% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
6.2M | -3.79% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.4M | +0.59% | |
|
John Hancock Funds III-International Growth Fund
|
3.2M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
465.1K | +6.79% |
Dividend History
Updated 2026/08/09| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥38 | -42.4% |
| 2025 | ¥66 | +16.5% |
| 2024 | ¥57 | +13.3% |
| 2023 | ¥50 | +25.0% |
| 2022 | ¥40 | - |
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
Shionogi & Co., Ltd. Q1 Financial Summary (IFRS) for the Fiscal Year Ending March 2027 | April 1, 2026 to June 30, 2026
In the cumulative first quarter of the fiscal year ending March 2027, net sales/ revenue reached 163,310 million yen (up 63.7% YoY), operating income 66,911 million yen (up 90.6% YoY), and net income attributable to owners of the parent 97,696...
Read more -
Q1 FY2027 Financial Results Supplement
For Q1 of the 2026 fiscal year, revenue was 163.3 billion yen, a substantial year‑over‑year increase; full-year guidance is around 700.0 billion yen, with progress at 23.3%. Major drivers are higher overseas subsidiaries, exports, and the impact of the ViiV...
Read more -
[Shionogi & Company] 2026 First Quarter Results and HIV Business Update Materials
Disclosure of the 2026 first-quarter earnings overview and HIV business status. Highlights include trends in sales, operating income, and quarterly results, with emphasis on domestic and international sales composition and contributions by specific segments (LAVI, HIV-related products, etc.). Also explains...
Read more -
[Shionogi & Co., Ltd.] Completion of Share Buyback ｜ July 2026
Shionogi & Co., Ltd. disposed of 201,300 treasury shares on July 23, 2026, raising approximately 568 million yen. The shares were allocated to directors, executive officers, and organizational leaders as part of their stock-based compensation scheme.
Read more -
Initiatives Toward Realizing Management that Considers Capital Cost and Stock Price
Shionogi & Co., Ltd. is promoting the enhancement of management functions, operational efficiency, and corporate strategies aimed at realizing management that takes into account capital costs and stock prices. The company aims to maximize corporate value through proactive IR activities...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥3,388
Rating Score: 2.33 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
